Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA)

Study ID
STU 102010-089

Cancer Related

Healthy Volunteers

Study Sites

  • Children’s Medical Center (Dallas, Plano, Southlake)

Andrew Hebert

Principal Investigator
Joshua Koch, M.D.


This is a multi-center, prospective, randomized, controlled trial of therapeutic hypothermia as a treatment for pediatric cardiac arrest. a total of 750-950 subjects (300-350 out-of-hospital arrests and 450-600 in-hospital arrests) will be required for this study, divided among 15 centers in the uS; 60 subjects are expected to be enrolled at CMCD over 5 years, with the hopes that 50 will complete all study procedures.

Participant Eligibility

patient suffered cardiac arrest requiring chest compressions for at least
2 minutes (120 seconds) with ROSC/ROC for at least 20 minutes;
age greater than 48 hours (with a corrected gestational age of at least
38 weeks) and less than 18 years; AND
patient requires continuous mechanical ventilation; AND
the cardiac arrest was unplanned (i.e., not part of cardiac surgical

[HIP Inclusion Criteria]

* Enrolled in THAPCA clinical trial

* Be greater than or equal to three (3) kg

* Receiving morphine and/or midazolam or have received morphine and/or midazolam at most six hours prior to enrollment in THAPCA (continuous infusions or intermittent dosing)

* Informed Consent

Nursing Survey:
Any intensive care nurse employed in the (PICU)/(CICU) at a participating THAPCA clinical centers will be invited to participate. There are currently 35 THAPCA centers with additional sites being added monthly. Each PICU/CICU has between 50-150 intensive care nurses with differing levels of experience taking care of THAPCA patients. Any of the nurses who would like to respond will be encouraged to do so.